Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

The neuronal plasticity gene CRTC1 links survival with mitochondrial programs and tumor microenvironment features in Group 3 β medulloblastoma

View through CrossRef
Abstract CREB-regulated transcription coactivator 1 (CRTC1) regulates neuronal development, plasticity, and activity-dependent transcription, but its role in medulloblastoma (MB) remains poorly understood. We investigated expression of the CRTC1 gene during human cerebellar development and across pediatric brain tumors and examined its molecular and clinical associations in MB using public transcriptomic datasets. CRTC1 was broadly expressed in the developing cerebellum, with cell-state-specific variation within the granule-cell lineage. Among pediatric brain tumors, MB showed the highest median CRTC1 expression, which differed significantly among MB molecular groups and subtypes, with highest levels in Group 4 MB. High CRTC1 expression was associated with longer overall survival specifically in Group 3 β MB and remained significant after correction across the 12 molecular subtypes. Within Group 3 β tumors, CRTC1 expression was inversely associated with enrichment of mitochondrial and bioenergetic processes, including oxidative phosphorylation, mitochondrial organization, and mitochondrial translation, whereas CRTC1 -high and CRTC1 -low tumors displayed distinct transcriptional profiles. CRTC1 was also associated with selected cell-type-related transcriptional signatures related to the tumor microenvironment. These findings identify CRTC1 as a marker of biologically and clinically relevant transcriptional heterogeneity in Group 3 β MB and support further investigation of its functional and prognostic significance. Graphical abstract
Title: The neuronal plasticity gene CRTC1 links survival with mitochondrial programs and tumor microenvironment features in Group 3 β medulloblastoma
Description:
Abstract CREB-regulated transcription coactivator 1 (CRTC1) regulates neuronal development, plasticity, and activity-dependent transcription, but its role in medulloblastoma (MB) remains poorly understood.
We investigated expression of the CRTC1 gene during human cerebellar development and across pediatric brain tumors and examined its molecular and clinical associations in MB using public transcriptomic datasets.
CRTC1 was broadly expressed in the developing cerebellum, with cell-state-specific variation within the granule-cell lineage.
Among pediatric brain tumors, MB showed the highest median CRTC1 expression, which differed significantly among MB molecular groups and subtypes, with highest levels in Group 4 MB.
High CRTC1 expression was associated with longer overall survival specifically in Group 3 β MB and remained significant after correction across the 12 molecular subtypes.
Within Group 3 β tumors, CRTC1 expression was inversely associated with enrichment of mitochondrial and bioenergetic processes, including oxidative phosphorylation, mitochondrial organization, and mitochondrial translation, whereas CRTC1 -high and CRTC1 -low tumors displayed distinct transcriptional profiles.
CRTC1 was also associated with selected cell-type-related transcriptional signatures related to the tumor microenvironment.
These findings identify CRTC1 as a marker of biologically and clinically relevant transcriptional heterogeneity in Group 3 β MB and support further investigation of its functional and prognostic significance.
Graphical abstract.

Related Results

Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Abstract 6505: Targeting PINK1 reduces medulloblastoma progression in animal models
Abstract 6505: Targeting PINK1 reduces medulloblastoma progression in animal models
Abstract Medulloblastoma is a brain cancer that mainly arises during infancy and childhood. Medulloblastoma is the most common pediatric malignant brain tumor worldw...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...
Abstract 1872: Targeting MYC-driven medulloblastoma using inhibitors of glutamine metabolism.
Abstract 1872: Targeting MYC-driven medulloblastoma using inhibitors of glutamine metabolism.
Abstract Medulloblastoma is the most common malignant brain tumor in children. Currently, treatment consists of surgical resection, chemotherapy, and whole brain and...
Giant Sacrococcygeal Teratoma in Infant: Systematic Review
Giant Sacrococcygeal Teratoma in Infant: Systematic Review
Abstract Introduction Sacrococcygeal teratoma (SCT) is a rare embryonal tumor that occurs in the sacrococcygeal region, with an incidence of about 1 in 35,000 to 40,000 live births...
Data from PRC2 Heterogeneity Drives Tumor Growth in Medulloblastoma
Data from PRC2 Heterogeneity Drives Tumor Growth in Medulloblastoma
<div>Abstract<p>Intratumor epigenetic heterogeneity is emerging as a key mechanism underlying tumor evolution and drug resistance. Epigenetic abnormalities frequently o...
Data from PRC2 Heterogeneity Drives Tumor Growth in Medulloblastoma
Data from PRC2 Heterogeneity Drives Tumor Growth in Medulloblastoma
<div>Abstract<p>Intratumor epigenetic heterogeneity is emerging as a key mechanism underlying tumor evolution and drug resistance. Epigenetic abnormalities frequently o...

Back to Top